Related Experiment Video
Updated: Nov 18, 2025
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Therapeutic Approaches for the No-Option Refractory Angina Patient
Thomas J Povsic1, Timothy D Henry2, E Magnus Ohman1
1Department of Medicine, Program for Advanced Coronary Disease, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC (T.J.P., E.M.O.).
Insights
Patients with refractory angina, often deemed "no-option," face limited treatment choices. This review explores novel therapies and a multidisciplinary approach for managing this challenging coronary artery disease group.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Medicine
Background:
- Aging populations and improved survival increase patients with coronary artery disease (CAD).
- Refractory angina (RA) or anginal equivalents persist despite maximal medical therapy.
- These patients often exhaust conventional revascularization, leading to "no-option" status.
Purpose of the Study:
- To review the definition, prevalence, and outcomes of no-option refractory angina (NORA).
- To focus on novel therapeutic options for NORA patients.
- To propose a multidisciplinary management approach for NORA.
Main Methods:
- Literature review of refractory angina and "no-option" patient populations.
- Analysis of current and emerging treatment strategies.
- Discussion of a proposed multidisciplinary team approach.
Main Results:
- NORA represents a growing, complex patient subset with limited conventional options.
- Novel therapies are emerging for symptom management and improved outcomes.
- A multidisciplinary team approach is crucial for optimal evaluation and care.
Conclusions:
- Refractory angina in the absence of conventional options presents a significant clinical challenge.
- Innovative treatments and specialized care models are needed.
- Further research into novel therapies for NORA is essential.
Abstract:
The combination of an aging population and improved survival rates among patients with coronary artery disease has resulted in an increase in the number of patients with refractory angina or anginal equivalent symptoms despite maximal medical therapy. Patients with refractory angina are often referred to the cardiac catheterization laboratory; however, they have often exhausted conventional revascularization options; thus, this population is often deemed as having "no options." We review the definition, prevalence, outcomes, therapeutic options, and treatment considerations for no-option refractory angina patients and focus on novel therapies for this complex and challenging population. We propose a multidisciplinary team approach for the evaluation and management of patients with refractory angina, ideally in a designated clinic. The severe limitations and symptomatology experienced by these patients highlight the need for additional research into the development of innovative treatments.
Related Concept Videos
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:27Coronary Artery Disease V: Interprofessional Care
01:27Angina II: Classification
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...